Neal Flomenberg

Chief Scientific Officer • Tevogen

Dr. Flomenberg joined Tevogen as its Chief Scientific Officer in July of 2022 after a 40+ year career in academic medicine.  Prior to joining Tevogen, he served as Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

  • The first in human administration of Interleukin-2
  • Initial descriptions of immunologic recovery after allogeneic BMT including the first description of the spectratyping technique to assess T cell receptor diversity
  • The initial reports describing the mechanisms of immunologic tolerance after mismatched human bone marrow transplantation.
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation.
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage.

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintained an active practice until his departure from Jefferson and was continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including:

  • The Simon Gratz Award for Research Most Likely to influence Patient Care – 2003
  • The Leukemia Lymphoma Society Contributions to Mankind Award – 2006
  • The Pennsylvania State University Outstanding Science Alumnus Award – 2006
  • He was the inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Society’s Lifetime Achievement Award in 2018
  • Thomas Jefferson University’s Alumnus of the Year Award 2019

Also Speaking

Ryan Crisman

Chief Technical Officer • Umoja Biopharma

Jason B. Litten

Chief Medical Officer • Chimeric Therapeutics

John Rasko

Professor • University of Sydney

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.